Cited by 1,490Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Open access

Herbst, Roy S., Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E., Sandler, Alan, Kris, Mark G., Tran, Hai T., Klein, Pam, Li, Xin, Ramies, David, Johnson, David H., Miller, Vincent A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.02.840

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC. PATIENTS AND METHODS: TRIBUTE randomly assigned patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC to erlotinib 150 mg/d or placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib. Random assignment was stratified by stage, weight loss in the previous 6 months, measurable disease, and treatment center. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response (OR), and duration of response. RESULTS: There were 1,059 assessable patients (526 erlotinib; 533 placebo). Median survival for patients treated with erlotinib was 10.6 v 10.5 months for placebo (hazard ratio, 0.99; 95% CI, 0.86 to 1.16; P = .95). There was no difference in OR or median TTP. Patients who reported never smoking (72 erlotinib; 44 placebo) experienced improved OS in the erlotinib arm (22.5 v 10.1 months for placebo), though no other prespecified factors showed an advantage in OS with erlotinib. Erlotinib and placebo arms were equivalent in adverse events (except rash and diarrhea). CONCLUSION: Erlotinib with concurrent carboplatin and paclitaxel did not confer a survival advantage over carboplatin and paclitaxel alone in patients with previously untreated advanced NSCLC. Never smokers treated with erlotinib and chemotherapy seemed to experience an improvement in survival and will undergo further investigation in future randomized trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.840

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
DECLARATION OF HELSINKI.
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 401–500 of 1,000

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer
Liu, S. V., Camidge, D. R., Gettinger, S. N., Giaccone, G., Heist, R. S., Hodi, F. S., Ready, N., Zhang, W., Wallin, J. J., Funke, R. P., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.033 · Cited by 47
Medical management of brain metastases
Lauko, A. J., Rauf, Y., & Ahluwalia, M. S. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa015 · Cited by 51
Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy
Isobe, T., Herbst, R. S., & Onn, A. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.02.016 · Cited by 47
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—one with a remarkable thoracic response as well
Kuiper, J. L., & Smit, E. F. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.024 · Cited by 46
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
on behalf of the Scottish Gynaecological Cancer Trials Group, Vasey, P. A., Gore, M. E., Wilson, R. H., Rustin, G. J. S., Gabra, H., Guastalla, J. P., Pujade-Lauraine, É., Paul, J., Carty, K., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604371 · Cited by 46
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., Lodi, F., Nicoletti, G., Landuzzi, L., Lollini, P., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn625 · Cited by 45
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study
Twelves, C. J., Trigo, J. M., Jones, R. J., Rosa, F. D., Rakhit, A. K., Fettner, S. H., Wright, T., & Baselga, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.011 · Cited by 46
Select Clinical Trials of Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer with Emphasis on Phase III Outcomes
Fuster, L. M. B., & Sandler, A. B. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.011 · Cited by 46
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
Farhat, F. S., & Houhou, W. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013492001 · Cited by 45
Second-Line Therapy for Advanced NSCLC
Weiss, J. M., & Stinchcombe, T. E. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0096 · Cited by 45
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
Morán, T., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1858 · Cited by 44
Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non–Small-Cell Lung Cancer Cells
Liu, J., Li, W., Gao, S., Wang, F., Li, X., Yu, H., Fan, L., Wei, W., Wang, H., & Sun, G. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.03.006 · Cited by 43
EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis
Chen, P., Wang, L., Liu, B., Zhang, H., Liu, H., & Zou, Z. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0965-4 · Cited by 44
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer
West, H., Lilenbaum, R., Harpole, D. H., Wozniak, A. J., & Sequist, L. V. D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b27170 · Cited by 44
Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network
Ritzwoller, D. P., Carroll, N. M., Delate, T., Hornbrook, M. C., Kushi, L. H., Bowles, E. J. A., Freml, J. M., Huang, K., & Loggers, E. T. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.008 · Cited by 44
A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and Maintenance Gefitinib for Patients with Stage III Non-small Cell Lung Cancer
Petty, W. J., Ayala, D. N., Hinson, W. H., Lovato, J. F., Capellari, J., Oaks, T. E., Miller, A. A., & Blackstock, A. W. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c59a0e · Cited by 44
The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
Kwak, E. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0087 · Cited by 44
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies
de Mello, R. A. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i11.367 · Cited by 43
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study
Aerts, J. G. J. V., Codrington, H., Lankheet, N. A. G., Burgers, S. A., Biesma, B., Dingemans, A. C., Vincent, A. D., Dalesio, O., Groen, H. J. M., & Smit, E. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt341 · Cited by 44
Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non–Small Cell Lung Cancer
Gandara, D. R., Narayan, S., Lara, P. N., Goldberg, Z., Davies, A. M., Lau, D. H. M., Mack, P. C., Gumerlock, P. H., & Vijayakumar, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-9012 · Cited by 44
Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma
Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A., Wakelee, H. A., Neal, J. W., Backhus, L. M., & Shrager, J. B. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.07.034 · Cited by 44
Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Chiappori, A., Haura, E. B., Rodriguez, F. A., Boulware, D. C., Kapoor, R., Neuger, A. M., Lush, R. M., Padilla, B., Burton, M. K., Williams, C. C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1508 · Cited by 44
Cancer of the Lung
Araujo, L. H., Horn, L., Merritt, R. E., Shilo, K., Xu‐Welliver, M., & Carbone, D. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00069-4 · Cited by 47
Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo
Zhu, H., Cheng, H., Ren, Y., Liu, Z. G., Zhang, Y. F., & Luo, B. D. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1293-1 · Cited by 42
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
Tyrosine Kinase Inhibitors in Lung Cancer
Thomas, A., Rajan, A., & Giaccone, G. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.001 · Cited by 45
The epidermal growth factor receptor (EGRF) in lung cancer
Carcereny, E., Morán, T., Capdevila, L., Cros, S., Vilà, L., Gil, M. D. L. L., Remón, J., & Rosell, R. (2015) · Translational Respiratory Medicine · doi:10.1186/s40247-015-0013-z · Cited by 44
EGFR genomic alterations in cancer prognostic and predictive values
Russo, A. D. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e296 · Cited by 43
Independent Review of Interstitial Lung Disease Associated with Death in TRIBUTE (Paclitaxel and Carboplatin with or without Concurrent Erlotinib) in Advanced Non-small Cell Lung Cancer
Yoneda, K. Y., Shelton, D. K., Beckett, L. A., & Gandara, D. R. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318060d329 · Cited by 43
Selection of extreme phenotypes: the role of clinical observation in translational research
Perez‐Gracia, J. L., Gúrpide, A., Ruiz-Ilundáin, M. G., Alegría, C. A., Colomer, R., García‐Foncillas, J., & Melero, I. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0487-7 · Cited by 45
Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Gerber, D. E., Gupta, P. K., Dellinger, M. T., Toombs, J. E., Peyton, M., Duignan, I. J., Malaby, J., Bailey, T., Burns, C. A., Brekken, R. A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0431 · Cited by 42
Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
Mita, A. C., Papadopoulos, K. P., de Jonge, M. J. A., Schwartz, G. H., Verweij, J., Mita, M. M., Ricart, A. D., Chu, Q. S.-C., Tolcher, A. W., Wood, L., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.332 · Cited by 43
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
Zarogoulidis, P., Kontakiotis, T., Karaiskos, Boutsikou, Zarogoulidis, K., Sakas, Darwiche, Hohenforst‐Schmidt, W., Tsakiridis, K., Galaktidou, et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s42245 · Cited by 43
Afatinib for the treatment of metastatic non-small cell lung cancer
Joshi, M., Rizvi, S., & Belani, C. P. (2015) · Cancer Management and Research · doi:10.2147/cmar.s51808 · Cited by 43
Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study
Goto, Y., Tanai, C., Yoh, K., Hosomi, Y., Sakai, H., Kato, T., Kaburagi, T., Nishio, M., Kim, Y., Inoue, A., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000214 · Cited by 40
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
Yang, J. C., Cheng, Y., Murakami, H., Yang, P., He, J., Nakagawa, K., Kang, J. H., Kim, J.-H., Hozak, R. R., Nguyen, T. S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.008 · Cited by 42
Targeted Therapies in Lung Cancer
Chirieac, L. R., & Đačić, S. (2010) · Surgical pathology clinics · doi:10.1016/j.path.2010.04.001 · Cited by 41
Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies
Nedergaard, M. K., Hedegaard, C. J., & Poulsen, H. S. (2012) · BioDrugs · doi:10.2165/11599760-000000000-00000 · Cited by 40
Targeting VEGF in lung cancer
Das, M. S., & Wakelee, H. A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.669752 · Cited by 41
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer
Digumarti, R., Bapsy, P. P., Suresh, A. V., Bhattacharyya, G. S., Dasappa, L., Shan, J. S., & Gerber, D. E. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.010 · Cited by 41
Management of EGFR mutated nonsmall cell lung carcinoma patients
Grigoriu, B. D., Berghmans, T., & Meert, A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00156614 · Cited by 41
Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Rzepecki, A. K., Cheng, H., & McLellan, B. N. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.046 · Cited by 42
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer
Garon, E. B., Siegfried, J. M., Stabile, L. P., Young, P. A., Márquez‐Garbán, D. C., Park, D. J., Patel, R., Hu, E. H.-L., Sadeghi, S., Parikh, R. J., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.013 · Cited by 40
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg, M. B., & Edelman, M. J. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0020-6 · Cited by 41
Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review
Feld, R., Sridhar, S. S., Shepherd, F. A., Mackay, J. A., & Evans, W. K. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31597-5 · Cited by 41
A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
Iyer, R. V., & Bharthuar, A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903551283 · Cited by 42
Extending Survival of Stage IV Non-Small Cell Lung Cancer
Carnio, S., Novello, S., Mele, T., Levra, M. G., & Scagliotti, G. V. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.013 · Cited by 40
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
Ranson, M., Reck, M., Anthoney, A., Hanauske, A.-R., Dean, E. J., Melezínek, I., Klingelschmitt, G., Kletzl, H., Blatter, J., & Twelves, C. J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq246 · Cited by 40
Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
Massarelli, E., & Herbst, R. S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.007 · Cited by 40
Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
Wen, P. Y., Kesari, S., & Drappatz, J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.733 · Cited by 40
Cetuximab-based Therapy is Effective in Chemotherapy-naïve Patients with Advanced and Metastatic Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials
Ibrahim, E. M., Abouelkhair, K. M., Al-Masri, O. A., Chaudry, N. C., & Kazkaz, G. A. (2011) · Lung · doi:10.1007/s00408-011-9286-3 · Cited by 39
EGFR and KRAS Mutations, and ALK Fusions: Current Developments and Personalized Therapies for Patients with Advanced Non-Small-Cell Lung Cancer
de Mello, R. A., Madureira, P., Carvalho, L. S., Araújo, A., O'Brien, M. E. R., & Popat, S. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.177 · Cited by 39
Peptide ligands targeting integrin α3β1 in non-small cell lung cancer
Lau, D. H., Guo, L., Liu, R., Mařı́k, J., & Lam, K. S. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.03.003 · Cited by 39
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction
Kumarakulasinghe, N. B., Syn, N. L. X., Soon, Y. Y., Asmat, A., Zheng, H., Loy, E. Y., Pang, B., & Soo, R. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13458 · Cited by 39
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Emery, I. F., Battelli, C., Auclair, P. L., Carrier, K., & Hayes, D. M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-333 · Cited by 39
Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
Stinchcombe, T. E., & Socinski, M. A. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0019 · Cited by 39
The Role of Anti–Epidermal Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Therapies in the Treatment of Non–Small-Cell Lung Cancer
Langer, C. J., & Soria, J. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.011 · Cited by 39
Targeted therapies in lung cancer
Besse, B., Ropert, S., & Soria, J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm308 · Cited by 39
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38
Molecular Diagnostics of Lung Carcinomas
Đačić, S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0625-rair.1 · Cited by 38
New targets for non-small-cell lung cancer therapy
Alvarez, M., Roman, E., Santos, E. S., & Raez, L. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1423 · Cited by 38
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors
Dong, S., Zhang, X., Cheng, H., Zhu, J., Chen, Z., Yi-fang, Z., Xie, Z., & Wu, Y.-L. L. C. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1946-3 · Cited by 38
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Cadranel, J. L., Zalcman, G., & Sequist, L. V. D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00179409 · Cited by 39
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Gridelli, C., Maione, P., Bareschino, M. A., Schettino, C., Sacco, P. C., Ambrosio, R., Barbato, V., Falanga, M., & Rossi, A. (2010) · PubMed · Cited by 38
Management of advanced lung cancer in resource-constrained settings: a perspective from India
Singh, N., Aggarwal, A. N., & Behera, D. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.119 · Cited by 39
Lung Cancer
Maghfoor, I., & Perry, M. C. (2005) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2005.1 · Cited by 38
Subtyping Non–Small Cell Lung Cancer
Rossi, G., Pelosi, G., Barbareschi, M., Graziano, P., Cavazza, A., & Papotti, M. G. (2013) · International Journal of Surgical Pathology · doi:10.1177/1066896913489346 · Cited by 38
Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors
Krause, M., Gurtner, K., Deuse, Y., & Baumann, M. A. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903232835 · Cited by 38
Kushenflavonoids induce apoptosis in tumor cells by inhibition of NF‐κB activation and multiple receptor tyrosine kinase activities
Han, J. S., Sun, M., Cui, Y., Wang, T., Zhang, W., Guo, M., Yuan, Z., Liu, W., Zhang, M., Duan, J., et al. (2006) · Phytotherapy Research · doi:10.1002/ptr.2065 · Cited by 38
A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy
Cappuzzo, F., Novello, S., de Marinis, F., Selvaggi, G., Scagliotti, G. V., Barbieri, F., Maur, M., Papi, M., Pasquini, E., Bartolini, S., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.03.004 · Cited by 38
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer
Reck, M., & Crinò, L. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.015 · Cited by 41
EGFR Inhibitors as First-Line Therapy in Advanced Non-small Cell Lung Cancer
Fong, T., Morgensztern, D., & Govindan, R. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181645477 · Cited by 38
New directions in the management of advanced pancreatic cancer: a review
Rocha‐Lima, C. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282fc9d11 · Cited by 38
Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer
Blackhall, F. H., Shepherd, F. A., & Albain, K. S. (2005) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200504020-00001 · Cited by 38
Update on systemic therapy of advanced non-small-cell lung cancer
Čufer, T., & Knez, L. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.940327 · Cited by 37
Fulminant Hepatic Failure Secondary to Erlotinib
Liu, W., Makrauer, F. L., Qamar, A., Janne, P. A., & Odze, R. D. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.04.014 · Cited by 37
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
Ganti, A. K., & Reade (2009) · Biologics · doi:10.2147/btt.2009.3119 · Cited by 39
Biological Agents in Non-small Cell Lung Cancer: A Review of Recent Advances and Clinical Results with a Focus on Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor
Kelly, K. L., & Huang, C. H. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181758141 · Cited by 37
Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Cagle, P. T., & Allen, T. C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0508-ra · Cited by 36
Gefitinib in Non Small Cell Lung Cancer
Costanzo, R., Piccirillo, M. C., Sandomenico, C., Carillio, G., Montanino, A., Daniele, G., Giordano, P., Bryce, J., Feo, G. D., Maïo, M. D., et al. (2011) · BioMed Research International · doi:10.1155/2011/815269 · Cited by 37
Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?
Tsai, C., Chen, J., Stewart, D. J., Chiu, C., Lai, C.-L., Hsiao, S.-Y., Chen, Y.-M., & Chang, K.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182021ff5 · Cited by 36
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
Belani, C. P., Goss, G. D., & Blumenschein, G. R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.05.009 · Cited by 39
Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
Spilker, M. E., Chen, X., Visswanathan, R., Vage, C., Yamazaki, S., Li, G., Lucas, J., Bradshaw‐Pierce, E. L., & Vicini, P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1164 · Cited by 36
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
Carlson, J. J., Suh, K., Orfanos, P., & Wong, W. B. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0625-6 · Cited by 35
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
Symonds, L. K., Linden, H. M., Gadi, V. K., Korde, L. A., Rodler, E. T., Gralow, J. R., Redman, M. W., Baker, K. K., Wu, Q. V., Jenkins, I., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.12.008 · Cited by 36
EGFR inhibition in non-small cell lung cancer: current evidence and future directions
Chi, A., Remick, S. C., & Tse, W. W. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-2 · Cited by 35
Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada, M. M., Spiro, T. P., & Daw, H. A. (2011) · PubMed · Cited by 36
Current and Future Approaches in the Management of Non–Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.013 · Cited by 34
Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials
Funakoshi, T., Latif, A., & Galsky, M. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.004 · Cited by 35
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer
Stinchcombe, T. E., Peterman, A. H., Lee, C. B., Moore, D. T., Beaumont, J. L., Bradford, D. S., BAKRI, K. M., Taylor, M., Crane, J. M., Schwartz, G. H., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182210430 · Cited by 35
Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms
Carbone, D. P., & Felip, E. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.002 · Cited by 35
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer
Kim, E. S., Mauer, A. M., William, W. N., Tran, H. T., Liu, D., Lee, J. J., Windt, P., Hong, W. K., Vokes, E. E., & Herbst, R. S. (2009) · Cancer · doi:10.1002/cncr.24148 · Cited by 35
Point mutations of protein kinases and individualised cancer therapy
Davies, M. A., Hennessy, B. T., & Mills, G. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.16.2243 · Cited by 34
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
de Boer, R., Humblet, Y., Wolf, J., Nogová, L., Ruffert, K., Milenkova, T., Smith, R. P., Godwood, A., & Vansteenkiste, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn674 · Cited by 35
Target specificity and off-target effects as determinants of cancer drug efficacy
Shoshan, M. C., & Linder, S. T. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.3.273 · Cited by 35
Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy
Kanda, S., Horinouchi, H., Fujiwara, Y., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Kubota, K., Tamura, T., & Ohe, Y. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.016 · Cited by 34
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Hirsh, V. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s104177 · Cited by 36
Histology as a treatment effect modifier in advanced non‐small cell lung cancer: A systematic review of the evidence
Standfield, L., Weston, A. R., Barraclough, H., Kooten, M. V., & Pavlakis, N. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.02025.x · Cited by 34

Authors: Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., Ramies, D., Johnson, D. H., & Miller, V. A.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Herbst, Roy S.
Johnson, Bruce E.
Sandler, Alan
Kris, Mark G.
Tran, Hai T.
Li, Xin
Ramies, David
Johnson, David H.
Miller, Vincent A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 5892-5899
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.02.840
OpenAlex: W2162724777
Cited by: 1,490
References: 25
Citations by year: 2026: 9 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 19 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 32 · 2017: 48 · 2016: 56 · 2015: 83 · 2014: 79 · 2013: 122 · 2012: 96
FWCI: 123.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: erlotinib, carboplatin, paclitaxel, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, combination chemotherapy, never smokers, overall survival, time to progression, objective response, maintenance therapy
MeSH terms: Erlotinib Hydrochloride, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Placebos, Quinazolines, Survival Analysis, Carboplatin, Paclitaxel, Disease Progression, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks